NCT01095276View on ClinicalTrials.gov

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
AtelectasisVentilation, Mechanical
Interventions
DRUG

Pulmozyme (nebulized dornase alpha)

nebulized dornase alpha: 2.5 mg by in-line nebulizer BID

DRUG

Saline

Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).

Trial Locations (1)

07183

University of Medicine and Dentistry of New Jersey, Newark

All Listed Sponsors
lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT01095276 - Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients | Biotech Hunter | Biotech Hunter